Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Review

Immunotherapies targeting stimulatory pathways and beyond

Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Rami Manochakian, Yujie Zhao, Yanyan Lou

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Abstract

Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells escape immune surveillance by promoting immunosuppression. Immunotherapy targeting inhibitory molecules like anti-CTLA-4 and anti-PD-1/PD-L1 were developed to overcome these immunosuppressive effects. These agents have demonstrated remarkable, durable responses in a small subset of patients. The other mechanisms for enhancing anti-tumor activities are to target the stimulatory pathways that are expressed on T cells or other immune cells. In this review, we summarize current phase I/II clinical trials evaluating novel immunotherapies targeting stimulatory pathways and outline their advantages, limitations, and future directions.
Literature
1.
2.
3.
Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–98.PubMedCrossRef
4.
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11.PubMedCrossRef
5.
Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. Esmo Open. 2017;2(2):e000213.PubMedPubMedCentralCrossRef
6.
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.PubMedPubMedCentralCrossRef
7.
DeBerardinis RJ. Tumor microenvironment, metabolism, and immunotherapy. N Engl J Med. 2020;382(9):869–71.PubMedCrossRef
8.
Giraldo NA, Sanchez-Salas R, Peske JD, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45–53.PubMedCrossRef
9.
10.
Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–80.PubMedCrossRef
11.
Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39–48.PubMedCrossRef
12.
van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655–67.PubMedCrossRef
13.
Aftimos P, Rolfo C, Rottey S, et al. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies. Clin Cancer Res. 2017;23(21):6411–20.PubMedCrossRef
14.
Burris HA, Infante JR, Ansell SM, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol. 2017;35(18):2028–36.PubMedCrossRef
15.
Sanborn RE, Pishvaian MJ, Callahan MK, et al. Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: phase (Ph) 1/2 clinical trial results. J Clin Oncol. 2018;36(15_suppl):3001–3001.CrossRef
16.
Silence K, Dreier T, Moshir M, et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2):523–32.PubMedCrossRef
17.
18.
Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today. 1999;20(11):488–93.PubMedCrossRef
19.
20.
Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175–86.PubMedCrossRef
21.
Grilley-Olson JE, Curti BD, Smith DC, et al. SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):3093–3093.CrossRef
22.
Bajor DL, Mick R, Riese MJ, et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 2018;7(10):e1468956.PubMedPubMedCentralCrossRef
23.
Calvo E, Moreno V, Perets R, et al. A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):2527–2527.CrossRef
24.
Kluger H, Weiss SA, Olszanski AJ, et al. Abstract CT089: phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Res. 2019;79(13 Supplement):CT089.CrossRef
25.
Qi X, Li F, Wu Y, et al. Optimization of 4–1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity. Nat Commun. 2019;10(1):2141.PubMedPubMedCentralCrossRef
26.
Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4–1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49–57.PubMedCrossRef
27.
28.
Sanmamed MF, Etxeberria I, Otano I, Melero I. Twists and turns to translating 4–1BB cancer immunotherapy. Sci Transl Med. 2019;11(496):eaax4738.PubMedCrossRef
29.
Tolcher AW, Sznol M, Hu-Lieskovan S, et al. Phase Ib study of utomilumab (PF-05082566), a 4–1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349–57.PubMedCrossRef
30.
Zhang L, Zhao H, Ma Y, et al. A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma. J Clin Oncol. 2020;38(15_suppl):3105–3105.CrossRef
31.
Willoughby J, Griffiths J, Tews I, Cragg MS. OX40: structure and function—what questions remain? Mol Immunol. 2017;83:13–22.PubMedCrossRef
32.
33.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50–66.PubMedCrossRef
34.
Goldman JW, Piha-Paul SA, Curti BD, et al. Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. J Clin Oncol. 2020;38(15_suppl):3003–3003.CrossRef
35.
Postel-Vinay S, Lam VK, Ros W, et al. Abstract CT150: a first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/− pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1). Cancer Res. 2020;80(16 Supplement):CT150.CrossRef
36.
Kvarnhammar AM, Veitonmaki N, Hagerbrand K, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J Immunother Cancer. 2019;7(1):103.PubMedPubMedCentralCrossRef
37.
Yachnin J, Ullenhag GJ, Carneiro A, et al. A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody. J Clin Oncol. 2020;38(15_suppl):3061–3061.CrossRef
38.
Yachnin J, Ullenhag GJ, Carneiro A, et al. Abstract CT145: a first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody. Cancer Res. 2020;80(16 Supplement):CT145.CrossRef
39.
Jimeno A, Gupta S, Sullivan R, et al. Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. In: AACR; 2020.
40.
Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer. 2016;67:1–10.PubMedCrossRef
41.
42.
Geva R, Voskoboynik M, Dobrenkov K, et al. First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer. 2020;126(22):4926–35.PubMedCrossRef
43.
Geva R, Voskoboynik M, Beebe AM, et al. First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):3029–3029.CrossRef
44.
Tran B, Carvajal RD, Marabelle A, et al. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018;6(1):93.PubMedPubMedCentralCrossRef
45.
Heinhuis KM, Carlino M, Joerger M, et al. Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors: a phase 1/2a dose-escalation and cohort-expansion clinical trial. JAMA Oncol. 2020;6(1):100–7.PubMedCrossRef
46.
Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13(6):433–44.PubMedCrossRef
47.
48.
Ju X, Huang P, Chen M, Wang Q. Liver X receptors as potential targets for cancer therapeutics. Oncol Lett. 2017;14(6):7676–80.PubMedPubMedCentral
49.
Killock D. Immunotherapy: targeting MDSCs with LXR agonists. Nat Rev Clin Oncol. 2018;15(4):200–1.PubMed
50.
Komati R, Spadoni D, Zheng S, Sridhar J, Riley KE, Wang G. Ligands of therapeutic utility for the liver X receptors. Molecules (Basel, Switzerland). 2017;22(1):88.CrossRef
51.
Lim E, Hamilton EP, Redman R, et al. Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts. Cancer Res. 2020;80(16 Supplement):CT146.CrossRef
52.
Mita MM, Mita AC, Chmielowski B, et al. Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies. J Clin Oncol. 2018;36(15_suppl):3095–3095.CrossRef
53.
Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8.PubMedCrossRef
54.
Hofer T, Krichevsky O, Altan-Bonnet G. Competition for IL-2 between regulatory and effector T cells to chisel immune responses. Front Immunol. 2012;3:268.PubMedPubMedCentralCrossRef
55.
56.
57.
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11(2):257–66.PubMedPubMedCentralCrossRef
58.
Soerensen MM, Ros W, Rodriguez-Ruiz ME, et al. Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP). J Clin Oncol. 2018;36(15_suppl):e15155–e15155.CrossRef
59.
Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28(33):4969–75.PubMedPubMedCentralCrossRef
60.
Albertini MR, Yang RK, Ranheim EA, et al. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018;67(10):1647–58.PubMedPubMedCentralCrossRef
61.
Vaishampayan UN, Fishman MN, Cho DC, et al. Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):TPS2649–TPS2649.CrossRef
62.
Vaishampayan UN, Muzaffar J, Velcheti V, et al. Abstract P447: ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial. Journal for ImmunoTherapy of Cancer, 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1. 2019;7(1):282.
63.
Siefker-Radtke AO, Fishman MN, Balar AV, et al. NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02. J Clin Oncol. 2019;37(7_suppl):388–388.CrossRef
64.
Diab A, Puzanov I, Maio M, et al. Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study. Journal for ImmunoTherapy of Cancer, 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2. 2019;7(1):283.
65.
Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012;33(1):35–41.PubMedCrossRef
66.
Patidar M, Yadav N, Dalai SK. Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev. 2016;31:49–59.PubMedCrossRef
67.
68.
Wrangle JM, Velcheti V, Patel MR, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704.PubMedPubMedCentralCrossRef
69.
Romee R, Cooley S, Berrien-Elliott MM, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018;131(23):2515–27.PubMedPubMedCentralCrossRef
70.
Van der Meer JMR, Maas RJA, Guldevall K, et al. IL-15 superagonist N-803 improves IFNgamma production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells. Cancer Immunol Immunother. 2020.
71.
Wrangle JM, Rubinstein MP, Mart C, et al. Phase I trial characterizing the pharmacokinetic profile and NK and CD8+ t cell expansion with n-803, a chimeric IL-15 superagonist, in healthy volunteers. J Clin Oncol. 2020;38(15_suppl):e15008–e15008.CrossRef
72.
73.
Sek K, Molck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci. 2018;19(12):3837.PubMedCentralCrossRef
74.
Jacobson KA, Merighi S, Varani K, et al. A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy. Med Res Rev. 2018;38(4):1031–72.PubMedCrossRef
75.
Gessi S, Varani K, Merighi S, et al. Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol. 2004;65(3):711–9.PubMedCrossRef
76.
Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13(12):842–57.PubMedCrossRef
77.
Bar-Yehuda S, Stemmer SM, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008;33(2):287–95.PubMed
78.
Stemmer SM, Manojlovic NS, Marinca MV, et al. A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(15_suppl):2503–2503.CrossRef
79.
Zhou H, Liao J, Aloor J, et al. CD11b/CD18 (Mac-1) is a novel surface receptor for extracellular double-stranded RNA to mediate cellular inflammatory responses. J Immunol. 2013;190(1):115–25.PubMedCrossRef
80.
Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128–41.PubMedCrossRef
81.
Panni RZ, Herndon JM, Zuo C, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019;11(499):eaau9240.PubMedPubMedCentralCrossRef
82.
Rasco DW, Bendell JC, Wang-Gillam A, et al. A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36). J Clin Oncol. 2020;38(15_suppl):3085–3085.CrossRef
83.
84.
85.
Berger G, Marloye M, Lawler SE. Pharmacological modulation of the STING pathway for cancer immunotherapy. Trends Mol Med. 2019;25(5):412–27.PubMedCrossRef
86.
Sokolowska O, Nowis D. STING signaling in cancer cells: important or not? Arch Immunol Ther Exp (Warsz). 2018;66(2):125–32.CrossRef
87.
Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018–30.PubMedPubMedCentralCrossRef
88.
Meric-Bernstam F, Sandhu SK, Hamid O, et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J Clin Oncol. 2019;37(15_suppl):2507–2507.CrossRef
89.
Shi M, Chen X, Ye K, Yao Y, Li Y. Application potential of toll-like receptors in cancer immunotherapy: systematic review. Medicine. 2016;95(25):e3951.PubMedPubMedCentralCrossRef
90.
91.
Bhatia S, Miller NJ, Lu H, et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with merkel cell carcinoma. Clin Cancer Res. 2019;25(4):1185–95.PubMedCrossRef
92.
93.
Dowling JK, Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clin Transl Immunol. 2016;5:e85.CrossRef
94.
Garcia-Manero G, Jabbour EJ, Konopleva MY, et al. A clinical study of tomaralimab (OPN-305), a toll-like receptor 2 (TLR-2) antibody, in heavily pre-treated transfusion dependent patients with lower risk myelodysplastic syndromes (MDS) that have received and failed on prior hypomethylating agent (HMA) therapy. Blood. 2018;132(Supplement 1):798–798.CrossRef
95.
Seo YD, Zhou J, Morse K, et al. Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically. J Clin Oncol. 2018;36(5_suppl):71.CrossRef
96.
Janku F, Han S-W, Doi T, et al. 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. J ImmunoTherapy Cancer. 2020;8(Suppl 3):A230.
97.
Shayan G, Kansy BA, Gibson SP, et al. Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals. Clin Cancer Res. 2018;24(1):62–72.PubMedCrossRef
98.
Ferris RL, Saba NF, Gitlitz BJ, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial. JAMA Oncol. 2018;4(11):1583–8.PubMedPubMedCentralCrossRef
99.
Mullins SR, Vasilakos JP, Deschler K, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J Immunother Cancer. 2019;7(1):244.PubMedPubMedCentralCrossRef
100.
Siu L, Brody J, Gupta S, et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020;8(2):e001095.PubMedPubMedCentralCrossRef
101.
Diab A, Curti B, Bilen M, et al. 368 REVEAL: phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors. J Immunother Cancer. 2020;8(Suppl 3):A224–5.
102.
Babiker HM, Subbiah V, Ali A, et al. Abstract CT134: tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors. Cancer Res. 2020;80(16 Supplement):CT134.CrossRef
103.
Babiker HM, Borazanci EH, Subbiah V, et al. Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125. J Clin Oncol. 2018;36(15_suppl):e15150–e15150.CrossRef
104.
Thomas M, Ponce-Aix S, Navarro A, et al. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol. 2018;29(10):2076–84.PubMedPubMedCentralCrossRef
105.
106.
107.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–24.PubMedCrossRef
108.
Beug ST, Beauregard CE, Healy C, et al. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat Commun. 2017;8:14278.PubMedCentralCrossRef
109.
Schilder RJ, Albertella M, Strauss JF, et al. Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: results from the dose-escalation phase of BPT-201. J Clin Oncol. 2019;37(15_suppl):2506–2506.CrossRef
110.
Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60(6):273–6.PubMedCrossRef
111.
Zboralski D, Hoehlig K, Eulberg D, Fromming A, Vater A. Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade. Cancer Immunol Res. 2017;5(11):950–6.PubMedCrossRef
112.
113.
Liehn EA, Tuchscheerer N, Kanzler I, et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol. 2011;58(23):2415–23.PubMedCrossRef
114.
Xue LJ, Mao XB, Ren LL, Chu XY. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. Cancer Med. 2017;6(6):1424–36.PubMedPubMedCentralCrossRef
115.
Halama N, Williams A, Prüfer U, et al. Abstract CT117: phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer. Cancer Res. 2020;80(16 Supplement):CT117.CrossRef
116.
Halama N, Pruefer U, Frömming A, et al. Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer. J Clin Oncol. 2019;37(15):e14143–e14143.CrossRef
117.
Halama N, Williams A, Suarez-Carmona M, et al. 1537P Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer. Ann Oncol. 2020;31:S944.CrossRef
118.
Kaufman PA, Pernas Simon S, Martin M, et al. Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: dose-response analysis of efficacy from phase I single-arm trial. J Clin Oncol. 2020;38(15_suppl):e15209–e15209.CrossRef
119.
Pernas S, Martin M, Kaufman PA, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018;19(6):812–24.PubMedCrossRef
120.
Kaufman PA, Pernas Simon S, Martin M, et al. Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial. J Clin Oncol. 2019;37(15_suppl):2606.CrossRef
121.
Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 2016;6(10):1090–105.PubMedPubMedCentralCrossRef
122.
Sullivan RJ, Hong DS, Tolcher AW, et al. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):3013–3013.CrossRef
123.
Virone-Oddos A, Bonnevaux H, Lemaitre O, et al. Abstract 3258: Discovery and characterization of SAR260301, a novel PI3Kβ-selective inhibitor in clinical development for the treatment of PTEN-deficient tumors. Can Res. 2013;73(8 Supplement):3258–3258.CrossRef
124.
Bedard PL, Davies MA, Kopetz S, et al. First-in-human trial of the PI3Kbeta-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. 2018;124(2):315–24.PubMedCrossRef
125.
126.
127.
Yu Y, Suryo Rahmanto Y, Lee M-H, et al. Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. Oncogene. 2018;37(28):3778–89.PubMedPubMedCentralCrossRef
128.
Krisenko MO, Geahlen RL. Calling in SYK: SYK’s dual role as a tumor promoter and tumor suppressor in cancer. Biochem Biophys Acta. 2015;1853(1):254–63.PubMedCrossRef
129.
Fueyo J, Alonso MM, Parker Kerrigan BC, Gomez-Manzano C. Linking inflammation and cancer: the unexpected SYK world. Neuro Oncol. 2018;20(5):582–3.PubMedPubMedCentral
130.
Krisenko MO, Geahlen RL. Calling in SYK: SYK’s dual role as a tumor promoter and tumor suppressor in cancer. Biochim Biophys Acta. 2015;1853(1):254–63.PubMedCrossRef
131.
Juric D, Olszanski AJ, Vaishampayan UN, et al. Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):e15124.CrossRef
132.
Diab S, Kumarasiri M, Yu M, et al. MAP kinase-interacting kinases–emerging targets against cancer. Chem Biol. 2014;21(4):441–52.PubMedCrossRef
133.
Dreas A, Mikulski M, Milik M, Fabritius CH, Brzozka K, Rzymski T. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors. Curr Med Chem. 2017;24(28):3025–53.PubMedCrossRef
134.
135.
Cerezo M, Guemiri R, Druillennec S, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018;24(12):1877–86.PubMedCrossRef
136.
137.
El-Khoueiry AB, Tchekmedyian N, Sanborn RE, et al. A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment. J Clin Oncol. 2020;38(15_suppl):3112.CrossRef
138.
Conte M, De Palma R, Altucci L. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int J Biochem Cell Biol. 2018;98:65–74.PubMedCrossRef
139.
Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414.PubMedCentralCrossRef
140.
Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond). 2013;124(11):651–62.CrossRef
141.
142.
Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011;1816(1):80–8.PubMedPubMedCentral
143.
Sando R 3rd, Gounko N, Pieraut S, Liao L, Yates J III, Maximov A. HDAC4 governs a transcriptional program essential for synaptic plasticity and memory. Cell. 2012;151(4):821–34.PubMedPubMedCentralCrossRef
144.
145.
Park SY, Jun JA, Jeong KJ, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep. 2011;25(6):1677–81.PubMed
146.
Triplett TA, Holay N, Kottapalli S, VanDenBerg C, Capasso A. Elucidating the role of HDACs in T cell biology and comparing distinct HDAC inhibitors in augmenting responses to cancer immunotherapy. J Immunol. 2020;204(1 Supplement):165.123.
147.
148.
Knox T, Sahakian E, Banik D, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9(1):6136.PubMedPubMedCentralCrossRef
149.
Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Brit J Cancer. 2006;95(Suppl 1):S2–6.CrossRefPubMedCentral
150.
Pili R, Quinn DI, Albany C, et al. Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients. J Clin Oncol. 2019;37(15_suppl):2572.CrossRef
151.
Tsimberidou AM, Beer P, Bendall J, et al. Abstract CT151: phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors. Cancer Res. 2020;80(16_suppl):CT151.CrossRef
152.
153.
Proia DA, Kaufmann GF. Targeting heat-shock protein 90 (HSP90) as a complementary strategy to immune checkpoint blockade for cancer therapy. Cancer Immunol Res. 2015;3(6):583–9.PubMedCrossRef
154.
Mbofung RM, McKenzie JA, Malu S, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017;8(1):451.PubMedPubMedCentralCrossRef
155.
156.
Do KT, Hays JL, Liu SV, et al. Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):2619.CrossRef
157.
Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 2016;37(10):872–81.PubMedCrossRef
158.
Sun L, Moore E, Berman R, et al. WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. Oncoimmunology. 2018;7(10):e1488359.PubMedPubMedCentralCrossRef
159.
Friedman J, Morisada M, Sun L, et al. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. J Immunother Cancer. 2018;6(1):59.PubMedPubMedCentralCrossRef
160.
Zhou L, Zhang Y, Chen S, et al. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. 2015;29(4):807–18.PubMedCrossRef
161.
Patel MR, Falchook GS, Wang JS-Z, et al. Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):2562.CrossRef
Metadata
Title
Immunotherapies targeting stimulatory pathways and beyond
Authors
Julian A. Marin-Acevedo
ErinMarie O. Kimbrough
Rami Manochakian
Yujie Zhao
Yanyan Lou
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01085-3

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Research

Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism

Research

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma

Review

Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins

Review

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Letter to the Editor

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

Research

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits